Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study

References

• Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262–3273. doi:10.1016/j.ejca.2013.04.02423751569
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320:43–52. doi:10.1001/jama.2018.746429971397
   PubMed Web of Science ®Google Scholar
• Leinonen MK, Nieminen P, Lonnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789. doi:10.1136/bmj.e778923197596
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249–257. doi:10.1016/S1470-2045(09)70360-220089449
   PubMed Web of Science ®Google Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–1588. doi:10.1056/NEJMoa07143017942871
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764–1772. doi:10.1016/S0140-6736(07)61450-017919718
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Nene BM, Dinshaw KA, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer. 2005;116:617–623. doi:10.1002/(ISSN)1097-021515818610
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589–1597. doi:10.1056/NEJMoa07320417942872
   PubMed Web of Science ®Google Scholar
• Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–532. doi:10.1016/S0140-6736(13)62218-724192252
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–F99. doi:10.1016/j.vaccine.2012.06.09523199969
   PubMed Web of Science ®Google Scholar
• Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer C. HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med. 2019;119:108–117. doi:10.1016/j.ypmed.2018.12.02130594536
   PubMed Web of Science ®Google Scholar
• Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240. doi:10.1136/bmj.l24030728133
   PubMed Web of Science ®Google Scholar
• Swedish National Board of Health and Welfare (Socialstyrelsen). Screening for Cervical Cancer. Recommendation and Evidence Base [in Swedish]. Stockholm, Sweden: Socialstyrelsen; 2015 Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-screeningprogram/2015-6-39.pdf. Accessed 116, 2019.
   Google Scholar
• Norwegian Cancer Registry (Kreftregisteret). HPV in Primary Screening [in Norwegian]. Oslo, Norway: Kreftregisteret; 2019 Available from https://www.kreftregisteret.no/screening/livmorhalsprogrammet/Helsepersonell/screeningstrategi-og-nasjonale-retningslinjer/HPV-i-primarscreening/. Accessed 116, 2019.
   Google Scholar
• Ronco G, Giorgi Rossi P, Giubilato P, et al. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiol Prev. 2015;3(Suppl 1):77–83.
   Google Scholar
• Australian Government, Department of Health. National Cervical Screening Program. Canberra, Australia: Australian Government Department of Health; 2019 Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-screening-1. Accessed 116, 2019.
   Google Scholar
• National Screening Unit, New Zealand. HPV Primary Screening. Auckland, New Zealand: National Screening Unit of New Zealand; 2017 Available from: https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme/hpv-primary-screening. Accessed 116, 2019.
   Google Scholar
• Veijalainen O, Kares S, Kujala P, et al. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30:150–156. doi:10.1111/cyt.2019.30.issue-230421573
   PubMed Web of Science ®Google Scholar
• Lamin H, Eklund C, Elfstrom KM, et al. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. BMJ Open. 2017;7:e014788. doi:10.1136/bmjopen-2016-014788
   PubMed Web of Science ®Google Scholar
• Zorzi M, Frayle H, Rizzi M, et al. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study. BJOG. 2017;124:1585–1593. doi:10.1111/1471-0528.1457528120382
   PubMed Web of Science ®Google Scholar
• Pasquale L, Giorgi Rossi P, Carozzi F, et al. Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme. J Med Screen. 2015;22:38–48. doi:10.1177/096914131456170725431452
   PubMed Web of Science ®Google Scholar
• Passamonti B, Gustinucci D, Giorgi Rossi P, et al. Cervical human papillomavirus (HPV) DNA primary screening test: results of a population-based screening programme in central Italy. J Med Screen. 2017;24:153–162. doi:10.1177/096914131666358027614992
   PubMed Web of Science ®Google Scholar
• Maggino T, Sciarrone R, Murer B, et al. Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. Br J Cancer. 2016;115:525–532. doi:10.1038/bjc.2016.21627490801
   PubMed Web of Science ®Google Scholar
• Del Mistro A, Frayle H, Ferro A, et al. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. J Med Screen. 2014;21:30–37. doi:10.1177/096914131452221924488593
   PubMed Web of Science ®Google Scholar
• Zorzi M, Del Mistro A, Farruggio A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG. 2013;120:1260–1267. doi:10.1111/1471-0528.1227223786222
   PubMed Web of Science ®Google Scholar
• Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. J Med Screen. 2010;17:79–86. doi:10.1258/jms.2010.00909220660436
   PubMed Web of Science ®Google Scholar
• Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018;142:1952–1958. doi:10.1002/ijc.v142.929235108
   PubMed Web of Science ®Google Scholar
• Aitken CA, van Agt HME, Siebers AG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study. BMC Med. 2019;17:228. doi:10.1186/s12916-019-1460-031829241
   PubMed Web of Science ®Google Scholar
• Danish National Board of Health. Screening Against Cervical Cancer – Recommendations [in Danish]. Copenhagen, Denmark: National Board of Health; 2012 Available from: https://www.sst.dk/~/media/B1211EAFEDFB47C5822E883205F99B79.ashx. Accessed 116, 2019.
   Google Scholar
• Danish National Board of Health. Screening Against Cervical Cancer – Recommendations [in Danish]. Copenhagen, Denmark: National Board of Health; 2018 Available from: https://www.sst.dk/da/sygdom-og-behandling/screening/~/media/5466AB0B06184ED0969BC31DA397610D.ashx. Accessed 116, 2019.
   Google Scholar
• Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health. 2011;39(Suppl):72–74. doi:10.1177/140349481039356321775357
   PubMed Web of Science ®Google Scholar
• Danish Quality Database for Cervical Cancer Screening. Annual Report 2017 [in Danish] Vejle, Denmark: Danish Quality Database for Cervical Cancer Screening; 2018 Available from: https://www.sundhed.dk/content/cms/82/4682_dkls-livmoderhalsscreening-aarsrapport-2017_endelig.pdf. Accessed 116, 2019.
   Google Scholar
• Nohr B, Frydshou D, Khan HS, et al. Danish Society of Obstetrics and Gynecology Clinical Guidelines. Diagnosis, Treatment and Control of Cervical Dysplasia [In Danish]. Copenhagen, Denmark: Danish Society of Obstetrics and Gynecology; 2013 Available from: http://gynobsguideline.dk/hindsgavl/Cervixdysplasi2012.pdf. Accessed 116 2019.
   Google Scholar
• Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health. 2011;39 7(Suppl):91–94.21775362
   PubMed Web of Science ®Google Scholar
• Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011;39 7(Suppl):95–98. doi:10.1177/140349481140848321775363
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39 7(Suppl):38–41. doi:10.1177/140349481039471721775349
   PubMed Web of Science ®Google Scholar
• Andersen JS, Olivarius N, Krasnik A. The Danish National Health Service Register. Scand J Public Health. 2011;39 7(Suppl):34–37. doi:10.1177/140349481039471821775348
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633. doi:10.1136/bmj.i363327469988
   PubMed Web of Science ®Google Scholar
• Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Di. 2015;19:91–96. doi:10.1097/LGT.0000000000000103
   PubMed Web of Science ®Google Scholar
• Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101–108. doi:10.1002/ijc.2763622610699
   PubMed Web of Science ®Google Scholar
• Burger EA, Nygard M, Gyrd-Hansen D, Moger TA, Kristiansen IS. Does the primary screening test influence women’s anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women. BMC Public Health. 2014;14:360. doi:10.1186/1471-2458-14-36024735469
   PubMed Web of Science ®Google Scholar
• Danish Quality Database for Cervical Cancer Screening. Annual Report 2010 [in Danish]. Copenhagen, Denmark: Danish Quality Database for Cervical Cancer Screening; 2010.
   Google Scholar
• Fontaine D, Narine N, Naugler C. Unsatisfactory rates vary between cervical cytology samples prepared using ThinPrep and SurePath platforms: a review and meta-analysis. BMJ Open. 2012;2(2):e000847. doi:10.1136/bmjopen-2012-000847
   Web of Science ®Google Scholar
• Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018;143:735–745. doi:10.1002/ijc.3126129341110
   PubMed Web of Science ®Google Scholar